Key Insights

Highlights

Success Rate

85% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

8.3%

2 terminated out of 24 trials

Success Rate

84.6%

-1.9% vs benchmark

Late-Stage Pipeline

25%

6 trials in Phase 3/4

Results Transparency

82%

9 of 11 completed with results

Key Signals

9 with results85% success

Data Visualizations

Phase Distribution

16Total
Not Applicable (3)
Early P 1 (1)
P 1 (1)
P 2 (5)
P 3 (5)
P 4 (1)

Trial Status

Completed11
Recruiting7
Terminated2
Enrolling By Invitation2
Not Yet Recruiting1
Active Not Recruiting1

Trial Success Rate

84.6%

Benchmark: 86.5%

Based on 11 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT07358234Early Phase 1Enrolling By InvitationPrimary

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

NCT06693531RecruitingPrimary

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

NCT07234825Not ApplicableRecruitingPrimary

Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis

NCT07112378Phase 3RecruitingPrimary

A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

NCT06598462Phase 2Active Not RecruitingPrimary

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

NCT07102329CompletedPrimary

BURDEN OF ESOPHAGEAL CANCER IN EOSINOPHILIC ESOPHAGITIS (ESCAPE STUDY)

NCT04394351Phase 3CompletedPrimary

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

NCT07156357RecruitingPrimary

Surface EMG Testing on Swallowing in EoE Patients

NCT07057986Not ApplicableNot Yet RecruitingPrimary

Trans-Cervical and Trans-abdominal Ultrasound for Monitoring Esophageal Thickness in Eosinophilic Esophagitis

NCT07012928RecruitingPrimary

Local Clinical and Immunological Responses in Eosinophilic Esophagitis (EoE) Patients, Role of Mucosal Barrier Function and Type II Inflammation

NCT06389994RecruitingPrimary

Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy

NCT06756581Not ApplicableEnrolling By InvitationPrimary

Tolerability of Baked Dairy Protein in Eosinophilic Esophagitis Patients With Cow Milk Protein Trigger

NCT04626609CompletedPrimary

Prostaglandin and Cannabinoid Receptors in EoE

NCT02605837Phase 3CompletedPrimary

A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

NCT03245840Phase 3TerminatedPrimary

Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

NCT02736409Phase 3CompletedPrimary

An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)

NCT05485779Phase 1CompletedPrimary

SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects

NCT06665971Phase 4RecruitingPrimary

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

NCT00762073Phase 2CompletedPrimary

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

NCT01642212Phase 2CompletedPrimary

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

Scroll to load more

Research Network

Activity Timeline